Trial Profile
Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Brostallicin (Primary) ; Doxorubicin
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Perivascular epithelioid cell tumours; Rhabdoid tumour; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Systems Medicine
- 12 Jul 2011 EudraCT reports status as recruiting in United Kingdom and completed in Netherlands and Germany.
- 12 Jul 2011 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 06 Jun 2010 Results were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO 2010).